{"organizations": [], "uuid": "38d5ab7a95a3eaa9897153f796d5e041de07c576", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/05/globe-newswire-amarin-announces-closing-of-underwriteras-purchase-of-additional-shares.html", "country": "US", "domain_rank": 767, "title": "Amarin Announces Closing of Underwriter’s Purchase of Additional Shares", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.35, "site_type": "news", "published": "2018-03-06T00:35:00.000+02:00", "replies_count": 0, "uuid": "38d5ab7a95a3eaa9897153f796d5e041de07c576"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/05/globe-newswire-amarin-announces-closing-of-underwriteras-purchase-of-additional-shares.html", "ord_in_thread": 0, "title": "Amarin Announces Closing of Underwriter’s Purchase of Additional Shares", "locations": [], "entities": {"persons": [{"name": "amarin", "sentiment": "negative"}], "locations": [{"name": "n.j.", "sentiment": "none"}, {"name": "dublin", "sentiment": "none"}, {"name": "ireland", "sentiment": "none"}, {"name": "bedminster", "sentiment": "none"}], "organizations": [{"name": "amarin corporation", "sentiment": "negative"}, {"name": "cantor fitzgerald & co.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "BEDMINSTER, N.J., and DUBLIN, Ireland, March 05, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares (\"ADSs\"), it has issued 1,438,356 additional ADSs, pursuant to the exercise of the underwriter’s option to purchase additional ADSs. The underwriter has agreed to purchase ADSs from us at a price of $3.41 per ADS, which includes an underwriting fee. The exercise of the option increases the size of the offering to an aggregate of approximately $75.2 million in gross proceeds to the Company. The purchase of the additional ADSs closed on March 5, 2018.\nCantor Fitzgerald & Co. is the sole book-running manager for the offering. The underwriter may offer the ADSs from time to time for sale in one or more transactions on The NASDAQ Global Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.\nAmarin intends to use the net proceeds from the offering to expand medical education and market awareness initiatives, including, in advance of REDUCE-IT results being known, pilot testing of new promotional initiatives for potential broader application following REDUCE-IT results, to increase its inventory balances for incremental inventory build prior to REDUCE-IT results and for general corporate and working capital purposes.\nThe securities described above are being offered by Amarin pursuant to a shelf registration statement on Form S-3ASR (No. 333-216385) previously filed with the Securities and Exchange Commission (the \"SEC\") on March 1, 2017 and automatically became effective upon filing. The securities may be offered only by means of a written prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov ( http://www.sec.gov ). Copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com .\nThis news release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.\nAbout Amarin\nAmarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Vascepa ® (icosapent ethyl) capsules, Amarin's first FDA approved product, are a highly-pure, omega-3 fatty acid product available by prescription.\nDisclosure Notice\nThis press release contains , within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements related to Amarin's public offering of American Depositary Shares, are that involve risks and uncertainties. Words such as \"intends,\" \"plans,\" \"expects,\" \"may,\" \"will\" and similar expressions are intended to identify . These are not promises or guarantees. These are based upon Amarin's current expectations. Actual events and results and the timing of events and results could differ materially from those anticipated in such . Among the factors that could cause actual results to differ materially from those described or projected herein are the following: risks related to the underwriter’s consummation of their obligation to purchase the securities, whether Amarin will be able to satisfy its obligations to close the offering and the risk that Amarin will not use the proceeds from the offering in the manner contemplated, as well as the risks, uncertainties and other matters detailed in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and the preliminary prospectus supplement relating to the offering and filed on January 29, 2018. Existing and prospective investors are cautioned not to place undue reliance on these , which speak only as of the date they were made. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as required by law.\nAmarin contact information:\nInvestor Relations:\nElisabeth Schwartz\nInvestor Relations and Corporate Communications\nAmarin Corporation plc\nIn U.S.: +1 (908) 719-1315\ninvestor.relations@amarincorp.com\nLee M. Stern\nTrout Group\nIn U.S.: +1 (646) 378-2992\nlstern@troutgroup.com\nMedia Inquiries:\nKristie Kuhl\nFinn Partners\nIn U.S.: +1 (212) 583-2791\nKristie.kuhl@finnpartners.com\nSource:Amarin Corporation plc", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/4e9ba297-8a1c-40bf-a8e8-4e7147b9d5de", "https://www.globenewswire.com/Tracker?data=l9xWaKltO78qAyIdf-dSi8S6vNiuF5rdFrcI_Sd1jUihyjGNhyolGMoATu2I_oUYPp7v5BBdVpdQ33u5ejxoWPbqTmrLttQCXT0n54QOLRk=", "https://www.globenewswire.com/Tracker?data=L--aWq8a2u9reV38iRxT28d2Gso7EKKpQA7W-oWHl0QcqaZHZXL_4bboq7qeWe0FGcdAJugZ9GoAuG8bwV9fHnvaprmgnFVbSuPQoKjrikYcs1BsTY1vt6PXqfM5RSoj", "https://www.globenewswire.com/Tracker?data=bMf4ZK0T41HyG2bwGhvbsCr2WQwN2DfilOV-TUzOcQWQ01P7Zt1ZuDyEsEMFQGcPU2uW31VMEpv0x5ICwFQDiQ8JcrNQ2JSImQkYHx2EQ_DConx6a9arWeWYCCVdnJu0Xurm727Uq1qy9FJE7SI-9A=="], "published": "2018-03-06T00:35:00.000+02:00", "crawled": "2018-03-06T02:44:13.006+02:00", "highlightTitle": ""}